CHC’s Jon Bigelow: Pharma marketers need to ‘state our value’ to Washington
Coalition for Healthcare Communication executive director Jon Bigelow identified issues to watch in Washington for pharma marketers at an MM&M event on Tuesday.
Policy
Gilead names Michael Boyd VP of government affairs, policy
Boyd has worked at AbbVie, Pfizer, and Schering-Plough.
Five things for pharma marketers to know: Tuesday, January 23, 2018
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
How will the pharma industry fare in 2018 under Trump?
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Five things for pharma marketers to know: Monday, December 4, 2017
CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech’s experimental hypertension drug; Republicans repeal Obamacare’s individual mandate
HHS nominee Alex Azar: Medicare Part B should negotiate drug prices
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
Limits on pharma payments to doctors back on policy menu
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Snubbing Intolerance: Frazier’s Path Was Disengagement
Merck CEO Kenneth Frazier’s exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Five things for pharma marketers to know: Wednesday, June 28, 2017
Lawmakers delay healthcare bill vote; Merck affected by cyberattack; more young people are having strokes
Five things for pharma marketers to know: Friday, June 23, 2017
Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar
